$REGN (REGENERON PHARMACEUTICALS) — 8-K: Regeneron CEO, CSO Get PSUs Tied to 10 New Product Filings, $30B New Revenue by 2035

Regeneron disclosed key terms of 2026 performance stock units for its CEO and CSO, awarding 10,000 PSUs per new product filing from January 1, 2026 through December 31, 2034, and 15,000 PSUs per new product approval through December 31, 2035. FDA approval of eligible supplemental filings earns 12,500 PSUs each. New product annual revenues are measured on fiscal years 2032 through 2035: zero PSUs below $10 billion, 250,000 PSUs at $10 billion, 900,000 PSUs at $18 billion, and 1,800,000 PSUs at $30 billion, with linear interpolation between levels above $10 billion. The awards follow a multi-year review citing roughly 50 pipeline product candidates, 16 approved or authorized medicines, four blockbusters each exceeding $1 billion in annual net product sales, and total shareholder return over 3,500% since the company became public.

Regeneron disclosed key terms of 2026 performance stock units for its CEO and CSO, awarding 10,000 PSUs per new product filing from January 1, 2026 through December 31, 2034, and 15,000 PSUs per new p